Abbott announced new four-year data showing the long-term and sustained relief that its proprietary BurstDR™ spinal cord stimulation (SCS) technology provides people with chronic pain, particularly ...

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the ...

Welcome to Abbott’s Fourth Quarter 2024 Earnings ... demand in international markets for our Eterna rechargeable spinal cord stimulation device. So in summary, we delivered another quarter ...

Abbott Laboratories (NYSE ... driven by strong demand in international markets for our Eterna rechargeable spinal cord stimulation device. So in summary, we delivered another quarter of strong ...

New research suggests that electrical spinal cord stimulation could improve muscle function for patients who have spinal ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...